Haldol dosage

Haloperidol use may lead to the development of symptoms that resemble
Parkinson's disease, but that are not caused by Parkinson's.
These symptoms may include a taut or mask-like expression on the face,
drooling, tremors, pill-rolling motions in the hands, cogwheel rigidity
(abnormal rigidity in muscles, characterized by jerky movements when the
muscle is passively stretched), and a shuffling gait. Taking the
anti-Parkinson drugs
benztropine
mesylate or
trihexyphenidyl
hydrochloride along with haloperidol help to control these symptoms.
Medication to control Parkinsonian-like symptoms may have to be continued
after haloperidol is stopped. This is due to different rates of
elimination of these drugs from the body.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [42] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 = mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [43] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .